Documento completo  |  Capítulo completo  |  Expandir índice  |  Versión HTML imprimible
Implications of the Doha Declaration on the Trips Agreement and Public Health - Health Economics and Drugs Series No. 012
(2002; 56 pages) [French] [Spanish] Ver el documento en el formato PDF
Documentos relacionados
At the Doha World Trade Organization (WTO) Ministerial Conference (9-14 November 2001), the WTO Members took the unprecedented step of adopting a special declaration on issues related to the Agreement on Trade-Related Aspects of Intellectual Property (TRIPS) and Public Health. Discussion on this declaration was one of the outstanding issues at the Conference, which launched a new round of trade negotiations on a broad range of issues. This was the first outcome of a process that started in early 2001 when, upon the request of the African Group, the Council for TRIPS agreed to deal specifically with the relationship between the TRIPS Agreement and Public Health. The confirmation that the TRIPS Agreement has left room for flexibility at the national level has important political and legal implications. It indicates that the pressures to impede the use of available flexibilities run counter to the spirit and purpose of the TRIPS Agreement. In legal terms, it means that panels and the Appellate Body must interpret the Agreement and the laws and regulations adopted to implement it in light of the public health needs of individual Members. The Doha Declaration is a strong political statement that can make it easier for developing countries to adopt measures necessary to ensure access to health care without the fear of being dragged into a legal battle. The Declaration is also a Ministerial decision with legal effects on the Members and on the WTO bodies, particularly the Dispute Settlement Body and the Council for TRIPS.
Índice de contenido
Ver el documentoForeword
Ver el documentoAcknowledgements
Ver el documentoAbbreviations and acronyms
Ver el documentoExecutive summary
Ver el documentoIntroduction
Ver el documentoScope
Ver el documentoThe role of TRIPS and IPRs
Abrir esta carpeta y ver su contenidoPublic health measures
Abrir esta carpeta y ver su contenidoFlexibility in TRIPS
Abrir esta carpeta y ver su contenidoMembers with insufficient or no manufacturing capacities
Ver el documentoTransfer of technology to LDCs
Ver el documentoExtension of transitional period for LDCs
Ver el documentoSpecial treatment under TRIPS
Ver el documentoLegal status of the Doha Declaration
Ver el documentoIssues not covered in the Declaration
Ver el documentoConclusions
Ver el documentoAnnex 1 - Doha Declaration on the TRIPS Agreement and Public Health
Ver el documentoAnnex 2 - Levels of development of pharmaceutical industry, by country
Ver el documentoReferences

Implications of the Doha Declaration on the Trips Agreement and Public Health - Health Economics and Drugs Series No. 012

Carlos M. Correa
University of Buenos Aires
June 2002

© World Health Organization [2002]

All rights reserved. Publications of the World Health Organization can be obtained from Marketing and Dissemination, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel: +41 22 791 2476; fax: +41 22 791 4857; email: Requests for permission to reproduce or translate WHO publications - whether for sale or for noncommercial distribution - should be addressed to Publications, at the above address (fax: +41 22 791 4806; email:

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.


Ir a la siguiente sección
El Portal de Información - Medicamentos Esenciales y Productos de Salud de la OMS fue diseñado y es mantenido por la ONG Human Info. Última actualización: le 1 diciembre 2019